Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan C Oosterwijk

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Breast Cancer Research and Treatment|June 23, 2006
Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancerMieke Kriege, Cecile T M Brekelmans, Inge Marie Obdeijn, et al.
Journal of Medical Genetics|November 29, 2013
Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutationsRichard M Brohet, Maria E Velthuizen, Frans B L Hogervorst, et al.
BMC Cancer|July 1, 2009
A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an exampleLeila Mohammadi, Maaike P Vreeswijk, Rogier Oldenburg, et al.
Journal of Community Genetics|September 4, 2020
Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-makingKelly Reumkens, Marly H E Tummers, Yil Severijns, et al.
Journal of Genetic Counseling|January 11, 2019
Online decision support for persons having a genetic predisposition to cancer and their partners during reproductive decision-makingKelly Reumkens, Marly H E Tummers, Joyce J G Gietel-Habets, et al.
Familial Cancer|May 31, 2018
The development of an online decision aid to support persons having a genetic predisposition to cancer and their partners during reproductive decision-making: a usability and pilot studyKelly Reumkens, Marly H E Tummers, Joyce J G Gietel-Habets, et al.
British Journal of Cancer|June 26, 2018
Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriersInge A P Derks-Smeets, Lieske H Schrijver, Christine E M de Die-Smulders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2010
BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening StudyAdriana J Rijnsburger, Inge-Marie Obdeijn, Reinoutje Kaas, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 30, 2012
Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combinedEveline A M Heijnsdijk, Ellen Warner, Fiona J Gilbert, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 9, 2014
Variation in mutation spectrum partly explains regional differences in the breast cancer risk of female BRCA mutation carriers in the NetherlandsJanet R Vos, Natalia Teixeira, Dorina M van der Kolk, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Breast Cancer Research and Treatment|June 23, 2006
Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancerMieke Kriege, Cecile T M Brekelmans, Inge Marie Obdeijn, et al.
Journal of Medical Genetics|November 29, 2013
Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutationsRichard M Brohet, Maria E Velthuizen, Frans B L Hogervorst, et al.
BMC Cancer|July 1, 2009
A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an exampleLeila Mohammadi, Maaike P Vreeswijk, Rogier Oldenburg, et al.
Journal of Community Genetics|September 4, 2020
Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-makingKelly Reumkens, Marly H E Tummers, Yil Severijns, et al.
Journal of Genetic Counseling|January 11, 2019
Online decision support for persons having a genetic predisposition to cancer and their partners during reproductive decision-makingKelly Reumkens, Marly H E Tummers, Joyce J G Gietel-Habets, et al.
Familial Cancer|May 31, 2018
The development of an online decision aid to support persons having a genetic predisposition to cancer and their partners during reproductive decision-making: a usability and pilot studyKelly Reumkens, Marly H E Tummers, Joyce J G Gietel-Habets, et al.
British Journal of Cancer|June 26, 2018
Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriersInge A P Derks-Smeets, Lieske H Schrijver, Christine E M de Die-Smulders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2010
BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening StudyAdriana J Rijnsburger, Inge-Marie Obdeijn, Reinoutje Kaas, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 30, 2012
Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combinedEveline A M Heijnsdijk, Ellen Warner, Fiona J Gilbert, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 9, 2014
Variation in mutation spectrum partly explains regional differences in the breast cancer risk of female BRCA mutation carriers in the NetherlandsJanet R Vos, Natalia Teixeira, Dorina M van der Kolk, et al.
Pageof 10